ATBF1 Inhibits Estrogen Receptor (ER) Function by Selectively Competing with AIB1 for Binding to the ER in ER-positive Breast Cancer Cells

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2010 Aug 20

PMID 20720010

Citations 30

Authors

Xue-Yuan Dong

Xiaodong Sun

Peng Guo

Qunna Li

Masakiyo Sasahara

Yoko Ishii

Jin-Tang Dong

Affiliations

Soon will be listed here.

Abstract

Loss of the q22 band of chromosome 16 is a frequent genetic event in breast cancer, and the candidate tumor suppressor gene, ATBF1, has been implicated in breast cancer by genomic deletion, transcriptional down-regulation, and association with better prognostic parameters. In addition, estrogen receptor (ER)-positive breast cancer expresses a higher level of ATBF1, suggesting a role of ATBF1 in ER-positive breast cancer. In this study, we examined whether and how ATBF1 affects the ER function in breast cancer cells. We found that ATBF1 inhibited ER-mediated gene transcription, cell growth, and proliferation in ER-positive breast cancer cells. In vitro and in vivo immunoprecipitation experiments revealed that ATBF1 interacted physically with the ER and that multiple domains in both ATBF1 and ER proteins mediated the interaction. Furthermore, we demonstrated that ATBF1 inhibited ER function by selectively competing with the steroid receptor coactivator AIB1 but not GRIP1 or SRC1 for binding to the ER. These findings not only support the concept that ATBF1 plays a tumor-suppressive role in breast cancer, they also provide a mechanism for how ATBF1 functions as a tumor suppressor in breast cancer.

Citing Articles

ZFHX3 acts as a tumor suppressor in prostate cancer by targeting FTO-mediated mA demethylation.

Hu Q, Yin J, Zhao S, Wang Y, Shi R, Yan K Cell Death Discov. 2024; 10(1):284.

PMID: 38871709 PMC: 11176170. DOI: 10.1038/s41420-024-02060-w.

A GGC-repeat expansion in ZFHX3 encoding polyglycine causes spinocerebellar ataxia type 4 and impairs autophagy.

Figueroa K, Gross C, Buena-Atienza E, Paul S, Gandelman M, Kakar N Nat Genet. 2024; 56(6):1080-1089.

PMID: 38684900 DOI: 10.1038/s41588-024-01719-5.

ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer.

Li M, Zheng Y, Li X, Shen X, Zhang T, Weng B BMC Cancer. 2022; 22(1):1280.

PMID: 36476423 PMC: 9727999. DOI: 10.1186/s12885-022-10380-2.

Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.

Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L Clin Cancer Res. 2022; 28(23):5066-5078.

PMID: 36215125 PMC: 9722539. DOI: 10.1158/1078-0432.CCR-22-2305.

Efp/TRIM25 and Its Related Protein, TRIM47, in Hormone-Dependent Cancers.

Azuma K, Inoue S Cells. 2022; 11(15).

PMID: 35954308 PMC: 9368238. DOI: 10.3390/cells11152464.

References

Zhang H, Yi X, Sun X, Yin N, Shi B, Wu H . Differential gene regulation by the SRC family of coactivators. Genes Dev. 2004; 18(14):1753-65. PMC: 478195. DOI: 10.1101/gad.1194704. View

Cleton-Jansen A, van Eijk R, Lombaerts M, Schmidt M, Vant Veer L, Philippo K . ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. BMC Cancer. 2008; 8:105. PMC: 2377272. DOI: 10.1186/1471-2407-8-105. View

Liu X, Yue P, Zhou Z, Khuri F, Sun S . Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004; 96(23):1769-80. DOI: 10.1093/jnci/djh322. View

Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H . Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol. 2007; 27(14):5105-19. PMC: 1951944. DOI: 10.1128/MCB.00162-07. View

Su Q, Hu S, Gao H, Ma R, Yang Q, Pan Z . Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncology. 2008; 75(3-4):159-68. DOI: 10.1159/000159267. View

Louie M, Revenko A, Zou J, Yao J, Chen H . Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol Cell Biol. 2006; 26(10):3810-23. PMC: 1489001. DOI: 10.1128/MCB.26.10.3810-3823.2006. View

Gronwald J, Jauch A, Cybulski C, Schoell B, Bohm-Steuer B, Lener M . Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. Int J Cancer. 2004; 114(2):230-6. DOI: 10.1002/ijc.20723. View

Sun X, Zhou Y, Otto K, Wang M, Chen C, Zhou W . Infrequent mutation of ATBF1 in human breast cancer. J Cancer Res Clin Oncol. 2006; 133(2):103-5. DOI: 10.1007/s00432-006-0148-y. View

Hartel A, Didier A, Pfaffl M, Meyer H . Characterisation of gene expression patterns in 22RV1 cells for determination of environmental androgenic/antiandrogenic compounds. J Steroid Biochem Mol Biol. 2003; 84(2-3):231-8. DOI: 10.1016/s0960-0760(03)00033-5. View

10.

Singh R, Kaluarachchi K, Chen M, Rayala S, Balasenthil S, Ma J . Solution structure and antiestrogenic activity of the unique C-terminal, NR-box motif-containing region of MTA1s. J Biol Chem. 2006; 281(35):25612-21. DOI: 10.1074/jbc.M604444200. View

11.

Cottone E, Orso F, Biglia N, Sismondi P, De Bortoli M . Role of coactivators and corepressors in steroid and nuclear receptor signaling: potential markers of tumor growth and drug sensitivity. Int J Biol Markers. 2001; 16(3):151-66. DOI: 10.1177/172460080101600301. View

12.

Chen C, Sun X, Guo P, Dong X, Sethi P, Cheng X . Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem. 2005; 280(50):41553-61. DOI: 10.1074/jbc.M506183200. View

13.

Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos M . BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999; 284(5418):1354-6. DOI: 10.1126/science.284.5418.1354. View

14.

Chen D, Ma H, Hong H, Koh S, Huang S, Schurter B . Regulation of transcription by a protein methyltransferase. Science. 1999; 284(5423):2174-7. DOI: 10.1126/science.284.5423.2174. View

15.

Iwase H, Omoto Y, Toyama T, Yamashita H, Hara Y, Sugiura H . Clinical significance of AIB1 expression in human breast cancer. Breast Cancer Res Treat. 2003; 80(3):339-45. DOI: 10.1023/A:1024916126532. View

16.

Dong X, Rodriguez C, Guo P, Sun X, Talbot J, Zhou W . SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008; 17(7):1031-42. PMC: 2923223. DOI: 10.1093/hmg/ddm375. View

17.

Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K . ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer. Clin Cancer Res. 2005; 11(1):193-8. View

18.

Murphy T, Pavlath G, Wang X, Boss V, Abbott K, Robida A . Retroviral vectors applied to gene regulation studies. Methods Enzymol. 2001; 345:539-51. DOI: 10.1016/s0076-6879(02)45045-8. View

19.

Morinaga T, Yasuda H, Hashimoto T, Higashio K, Tamaoki T . A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers. Mol Cell Biol. 1991; 11(12):6041-9. PMC: 361769. DOI: 10.1128/mcb.11.12.6041-6049.1991. View

20.

Henderson I . Risk factors for breast cancer development. Cancer. 1993; 71(6 Suppl):2127-40. DOI: 10.1002/1097-0142(19930315)71:6+<2127::aid-cncr2820711602>3.0.co;2-2. View